Sir Adrian Hill | |
|---|---|
| Born | |
| Education | Belvedere College |
| Alma mater | |
| Known for | Vaccinology |
| Spouses | |
| Scientific career | |
| Fields | Genetics Immunology Vaccines Malaria[1] |
| Institutions | |
| Thesis | The distribution and molecular basis of thalassaemia in Oceania (1986) |
| Doctoral advisor | John Brian Clegg David Weatherall |
| Website | www |
Sir Adrian Vivian Sinton Hill,KBE FRS FMedSci FRCP[2] is an Irish-British vaccinologist who is Director of theJenner Institute and Lakshmi Mittal and Family Professor of Vaccinology at theUniversity of Oxford, an honorary Consultant Physician in Infectious Diseases,[3] andFellow ofMagdalen College, Oxford.[4] Hill is a leader in the field of malaria vaccine development and was a co-leader of the research team which produced theOxford–AstraZeneca COVID-19 vaccine, along with ProfessorSarah Gilbert of the Jenner Institute and ProfessorAndrew Pollard of theOxford Vaccine Group.[5][1][6]
Hill was educated atBelvedere College in Dublin.[2] He began reading medicine atTrinity College Dublin, where he was elected aFoundation Scholar in 1978.[7] Thereupon he transferred toMagdalen College, Oxford for one year, but he ended up remaining in Oxford to complete the rest of his medical degree, qualifying in 1982.[8][4] He remained at theUniversity of Oxford for postgraduate studies and was awarded aDoctor of Philosophy degree in 1986[9] for research on the molecular genetics ofthalassemia supervised byJohn B. Clegg [Wikidata].[4][10]
During his time at theWellcome Trust Centre for Human Genetics his research group studied genetic susceptibility to infections such asmalaria,tuberculosis, andHIV. From 1997[11] he has developed candidate vaccines for malaria which produce cellular (T-cell) immunity and partial efficacy usingAdenovirus andModified vaccinia Ankara (MVA) viral vector vaccines in a prime-boost regime.[12] From 2005 he has played a leading role in the pre-clinical and clinical assessment of new chimpanzee adenoviral vaccine vectors, particularly ChAd63, ChAd3 and ChAdOx1.
His group has developed numerous candidate vaccines against malaria which have been tested inclinical trials in the UK and Africa.[13] In 2021 his group reported high efficacy of a new R21/matrix-M candidate vaccine in Burkina Faso children and this vaccine was licensed in 2024 following a phase III licensure trial.[14] In 2014, he led a clinical trial of anEbola vaccine based on chimpanzee adenoviral and MVA vector technology in response to theWest African Ebola virus epidemic.[12][15][16] In 2016 he co-founded Vaccitech plc, an OxfordUniversity spin-off company developing therapeutic and preventive vaccines based on viral vector technology.[17] In 2017 he led a successful major award application to Innovate UK to co-found the Vaccines Manufacturing and Innovation Centre (VMIC) in Harwell, Oxfordshire, one of the first purpose-built vaccine manufacturing centres for emergency response vaccines.[18] In response to the 2020 COVID-19 pandemic he worked with many others at Oxford to develop and partner the ChAdOx1 vector-based SARS-CoV-2 vaccine, notably with AstraZeneca and the Serum Institute of India, supporting large scale access for low and middle income countries.[19] Hill also signed a letter organized by1Day Sooner to advocate forhuman challenge trials in the United States.[20]
Hill has two children with his former wife, epidemiologistSunetra Gupta.
In 2021, he marriedSabina Murray.[2]
{{cite web}}:|last= has generic name (help)CS1 maint: multiple names: authors list (link)| International | |
|---|---|
| National | |
| Academics | |
| Other | |